Centro Jeronimo Of Ayanz

Pamplona, Spain

Centro Jeronimo Of Ayanz

Pamplona, Spain

Time filter

Source Type

San Roman B.,Institute Agrobiotecnologia Csic Upna Gobierno Of Navarra | De Andres X.,Institute Agrobiotecnologia Csic Upna Gobierno Of Navarra | Munoz P.-M.,Institute Agrobiotecnologia Csic Upna Gobierno Of Navarra | Obregon P.,Institute Agrobiotecnologia Csic Upna Gobierno Of Navarra | And 9 more authors.
Vaccine | Year: 2012

The development of effective vaccines against HIV-1 infection constitutes one of the major challenges in viral immunology. One of the protein candidates in vaccination against this virus is p24, since it is a conserved HIV antigen that has cytotoxic and helper T cell epitopes as well as B cell epitopes that may jointly confer enhanced protection against infection when used in immunization-challenge approaches. In this context, the adjuvant effect of EDA (used as EDAp24 fusion protein) and poly(I:C), as agonists of TLR4 and TLR3, respectively, was assessed in p24 immunizations using a recombinant Listeria monocytogenes HIV-1 Gag proteins (Lm-Gag, where p24 is the major antigen) for challenge in mice. Immunization with EDAp24 fusion protein together with poly(I:C) adjuvant induced a specific p24 IFN-γ production (Th1 profile) as well as protection against a Lm-Gag challenge, suggesting an additive or synergistic effect between both adjuvants. The combination of EDA (as a fusion protein with the antigen, which may favor antigen targeting to dendritic cells through TLR4) and poly(I:C) could thus be a good adjuvant candidate to enhance the immune response against HIV-1 proteins and its use may open new ways in vaccine investigations on this virus. © 2012 Elsevier Ltd.

Loading Centro Jeronimo Of Ayanz collaborators
Loading Centro Jeronimo Of Ayanz collaborators